PURPOSE: CKLF-like MARVEL transmembrane domain containing member 3 (CMTM3) is silenced in many kinds of cancers and inhibits tumor cells growth. We investigated the expression and role of CMTM3 in clear cell renal cell carcinoma (ccRCC). METHODS: The expression of CMTM3 was detected in ccRCC tissue microarray, specimens, and cell lines by immunohistochemistry, quantitative real-time polymerase chain reaction (qRT-PCR) and western blot, respectively. After transfected with CMTM3 plasmid or vector, the proliferation and migration of ccRCC 786-0 cells were determined by MTT assay and transwell assay, respectively. Furthermore, the anchorage-independent growth of transfected cells was assessed using soft agar colony formation assay. RESULTS: CMTM3 was down-regulated in 84 % (63/75) of ccRCC tissues and its expression had no correlation with the gender, age, clinical staging and histologic grade. CMTM3 protein was undetectable by western blot in most detected ccRCC specimens and two RCC cell lines (786-0 and ACHN). qRT-PCR analysis showed that CMTM3 mRNA was dramatically down-regulated in 40 ccRCC cancer tissues as compared with the paired adjacent normal ones. Restoration of CMTM3 significantly suppressed the anchorage-independent growth, proliferation and migration of 786-0 cells. CONCLUSION: These results indicate that CMTM3 is significantly down-regulated in ccRCC and exerts remarkable tumor-suppressive functions in 786-0 cells. Reduction of CMTM3 expression may contribute to the pathogenesis of ccRCC and CMTM3 may be a potentially target for therapeutic strategy.
PURPOSE: CKLF-like MARVEL transmembrane domain containing member 3 (CMTM3) is silenced in many kinds of cancers and inhibits tumor cells growth. We investigated the expression and role of CMTM3 in clear cell renal cell carcinoma (ccRCC). METHODS: The expression of CMTM3 was detected in ccRCC tissue microarray, specimens, and cell lines by immunohistochemistry, quantitative real-time polymerase chain reaction (qRT-PCR) and western blot, respectively. After transfected with CMTM3 plasmid or vector, the proliferation and migration of ccRCC 786-0 cells were determined by MTT assay and transwell assay, respectively. Furthermore, the anchorage-independent growth of transfected cells was assessed using soft agar colony formation assay. RESULTS:CMTM3 was down-regulated in 84 % (63/75) of ccRCC tissues and its expression had no correlation with the gender, age, clinical staging and histologic grade. CMTM3 protein was undetectable by western blot in most detected ccRCC specimens and two RCC cell lines (786-0 and ACHN). qRT-PCR analysis showed that CMTM3 mRNA was dramatically down-regulated in 40 ccRCC cancer tissues as compared with the paired adjacent normal ones. Restoration of CMTM3 significantly suppressed the anchorage-independent growth, proliferation and migration of 786-0 cells. CONCLUSION: These results indicate that CMTM3 is significantly down-regulated in ccRCC and exerts remarkable tumor-suppressive functions in 786-0 cells. Reduction of CMTM3 expression may contribute to the pathogenesis of ccRCC and CMTM3 may be a potentially target for therapeutic strategy.
Authors: Haoqiang Ying; Hongwu Zheng; Kenneth Scott; Ruprecht Wiedemeyer; Haiyan Yan; Carol Lim; Joseph Huang; Sabin Dhakal; Elena Ivanova; Yonghong Xiao; Hailei Zhang; Jian Hu; Jayne M Stommel; Michelle A Lee; An-Jou Chen; Ji-Hye Paik; Oreste Segatto; Cameron Brennan; Lisa A Elferink; Y Alan Wang; Lynda Chin; Ronald A DePinho Journal: Proc Natl Acad Sci U S A Date: 2010-03-29 Impact factor: 11.205
Authors: W Han; Y Lou; J Tang; Y Zhang; Y Chen; Y Li; W Gu; J Huang; L Gui; Y Tang; F Li; Q Song; C Di; L Wang; Q Shi; R Sun; D Xia; M Rui; J Tang; D Ma Journal: Biochem J Date: 2001-07-01 Impact factor: 3.857
Authors: Yu Wang; Jisheng Li; Yan Cui; Ting Li; Ka Man Ng; Hua Geng; Henan Li; Xing-sheng Shu; Hongyu Li; Wei Liu; Bing Luo; Qian Zhang; Tony Shu Kam Mok; Wei Zheng; Xiaoyan Qiu; Gopesh Srivastava; Jun Yu; Joseph J Y Sung; Anthony T C Chan; Dalong Ma; Qian Tao; Wenling Han Journal: Cancer Res Date: 2009-06-09 Impact factor: 12.701
Authors: José Roberto F Caldeira; Erika C Prando; Francisco C Quevedo; Francisco A Moraes Neto; Cláudia A Rainho; Silvia R Rogatto Journal: BMC Cancer Date: 2006-03-02 Impact factor: 4.430
Authors: Ines Llaudo; Miguel Fribourg; M Edward Medof; Patricia Conde; Jordi Ochando; Peter S Heeger Journal: Am J Transplant Date: 2018-09-17 Impact factor: 8.086
Authors: Wael M Abdel-Rahman; Johanna E Lotsari-Salomaa; Sippy Kaur; Anni Niskakoski; Sakari Knuutila; Heikki Järvinen; Jukka-Pekka Mecklin; Päivi Peltomäki Journal: Gastroenterol Res Pract Date: 2016-03-07 Impact factor: 2.260